ArticlePakistan journal of medical sciences2026
Efficacy and safety of sintilimab in the treatment of sqNSCLC.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the efficacy and safety of sintilimab in the treatment of sqNSCLC. Methodology: This retrospective study enrolled 64 patients with advanced sqNSCLC receiving intervention at the Shijiazhuang People's Hospital according to the inclusion and exclusion criteria between January, 2022 to December, 2024 and were randomly divided into the observation and control groups, each including 32 patients with advanced sqNSCLC. The patients in the observation group received gemcitabine and sintilimab, as well as gemcitabine plus cisplatin, whereas patients in the control group received sintilimab sequentially with gemcitabine plus cisplatin. Compared to each other to evaluate the efficacy and safety of sintilimab in the treatment of advanced sqNSCLC. Results: After four cycles of treatment, the ORR of the control group patients with advanced sqNSCLC was significantly better than that of the observation group( Conclusion: Sintilimab, as a treatment option for advanced sqNSCLC, can safely improve the effectiveness of intervention in advanced sqNSCLC and prolong the survival of patients with sqNSCLC, with a good safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.